These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38784059)

  • 1. "ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in
    Luo FX; Ou SI
    Lung Cancer (Auckl); 2024; 15():69-73. PubMed ID: 38784059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
    Pang LL; Gan JD; Tan JR; Huang YH; Liao J; Liang WT; Deng PB; Fang WF
    Cancer; 2022 Nov; 128(21):3804-3814. PubMed ID: 36069292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
    Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
    Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
    Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
    J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
    Masood A; Kancha RK; Subramanian J
    Semin Oncol; 2019 Jun; 46(3):271-283. PubMed ID: 31558282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
    Sehgal K; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
    Oncologist; 2021 Apr; 26(4):281-287. PubMed ID: 32969527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
    Yang JC; Schuler M; Popat S; Miura S; Heeke S; Park K; Märten A; Kim ES
    J Thorac Oncol; 2020 May; 15(5):803-815. PubMed ID: 31931137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
    Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.
    Jiang Y; Fang X; Xiang Y; Fang T; Liu J; Lu K
    Curr Oncol; 2023 May; 30(6):5337-5349. PubMed ID: 37366888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
    Passaro A; de Marinis F; Tu HY; Laktionov KK; Feng J; Poltoratskiy A; Zhao J; Tan EH; Gottfried M; Lee V; Kowalski D; Yang CT; Srinivasa BJ; Clementi L; Jalikop T; Huang DCL; Cseh A; Park K; Wu YL
    Front Oncol; 2021; 11():709877. PubMed ID: 34307179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
    Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
    Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
    Moran T; Taus A; Arriola E; Aguado C; Dómine M; Rueda AG; Calles A; Cedrés S; Viñolas N; Isla D; Palmero R; Sereno M; Diaz V; Juan O; Marsé R; Martorell PM; Sánchez Torres JM;
    Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of uncommon
    Zhang T; Wan B; Zhao Y; Li C; Liu H; Lv T; Zhan P; Song Y
    Transl Lung Cancer Res; 2019 Jun; 8(3):302-316. PubMed ID: 31367543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
    Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Xu H; Yang G; Liu R; Yang Y; Li W; Li J; Hao X; Xing P; Wang Y
    Front Pharmacol; 2022; 13():976731. PubMed ID: 36188595
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
    Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT
    Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.
    Pham VL; Le TA; Pham CP; Hoa Nguyen TT; Do AT; Nguyen TK; Nguyen MH; Thu Hoang TA; Hao Vuong DT; Tam Nguyen DN; Khiem Dang V; Nguyen TO; Trang Vo TH; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Dung Nguyen K; Nguyen HG; Truong CM; Chau Pham TM; Nguyen TBP
    Ther Adv Med Oncol; 2024; 16():17588359241242972. PubMed ID: 38736554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib 30 mg in the treatment of common and uncommon
    Qian J; Ye X; Huang A; Qin R; Cai Y; Xue Y; Zhang S; Wang W; Xiong L; Gu A
    J Thorac Dis; 2022 Jun; 14(6):2169-2177. PubMed ID: 35813735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation.
    Dong W; Wang C; Wang C; Zhao K; Ma Z; Hu S
    Front Oncol; 2022; 12():999606. PubMed ID: 36425553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study.
    Lin Y; Chen L; Li R; Liu X; Li Q; Cai J; Du Y; Zhao G; Wang X; Shen Z; Liao Y; Chen Y; Xie L; Zhou Y; Huang Y
    Front Oncol; 2023; 13():1156647. PubMed ID: 37881485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.